Serum anti-neuronal antibodies in amyotrophic lateral sclerosis

References

• Matsumoto H, Hanson MR, Chad DA. Amyotrophic lateral sclerosis. Recent advances in pathogenesis and therapeutic trials. Arch Neurol 1988;45(2):189–202.
   PubMedGoogle Scholar
• Niebroj-Dobosz I, Jamrozik Z, Janik P, Anti-neural antibodies in serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients. Acta Neurol Scand 1999;100(4):238–43.
   PubMedGoogle Scholar
• Ikeda J, Kohriyama T, Nakamura S. Elevation of serum soluble E-selectin and antisulfoglucuronyl paragloboside antibodies in amyotrophic lateral sclerosis. Eur J Neurol 2000;7(5):541–7.
   PubMedGoogle Scholar
• Yamazaki T, Suzuki M, Irie T, Amyotrophic lateral sclerosis associated with IgG anti-GalNAc-GD1a antibodies. Clin Neurol Neurosurg 2008;110(7):722–4.
   PubMedGoogle Scholar
• Adams D, Kuntzer T, Burger D, Predictive values of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera. J Neuroimmunol 1991;32(3):223–30.
   PubMedGoogle Scholar
• Appel SH, Glenn Smith R, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci 1994;24(suppl):14–9.
   Google Scholar
• Drachman DB, Kuncl RW. Amyotrophic lateral sclerosis: an unconventional autoimmune disease? Ann Neurol 1989;26(2):269–74.
   PubMedGoogle Scholar
• Kornberg AJ, Pestronk A. The clinical and diagnostic role of anti-GMI antibody testing. Muscle Nerve 1994;17(1):100–4.
   PubMedGoogle Scholar
• Lamb NL, Patten BM. Clinical correlations of anti-GM1 antibodies in amyotrophic lateral sclerosis. Muscle Nerve 1991;14(10):1021–7.
   PubMedGoogle Scholar
• Haggiag S, Steiner-Birmanns B, Wirguin I, Seroconversion of anti-GM1 antibodies in patients with amyotrophic lateral sclerosis. Neurology 2004;63(4):755–6.
   PubMedGoogle Scholar
• Kornberg AJ. Anti-GM1 ganglioside antibodies: their role in the diagnosis and pathogenesis of immune-mediated motor neuropathies. J Clin Neurosci 2000;7(3):191–4.
   PubMedGoogle Scholar
• Niebroj-Dobosz I, Janik P, Kwieciński H. Serum IgM anti-GM1 ganglioside antibodies in lower motor neuron syndromes. Eur J Neurol 2004;11(1):13–6.
   PubMedGoogle Scholar
• Li F, Pestronk A. Autoantibodies to GM1 ganglioside: different reactivity to GM1-liposomes in amyotrophic lateral sclerosis and lower motor neuron disorders. J Neurol Sci 1991;104(2):209–14.
   PubMedGoogle Scholar
• Salazar-Grueso EF, Routbort MJ, Martin J, Polyclonal IgM anti-GM1 ganglioside antibody in patients with motor neuron disease and variants. Ann Neurol 1990;27(5):558–63.
   PubMedGoogle Scholar
• Stevens A, Weller M, Wiethölter H. A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993;56(4):361–4.
   PubMedGoogle Scholar
• Pestronk A, Adams RN, Cornblath D, Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis. Ann Neurol 1989;25(1):98–102.
   PubMedGoogle Scholar
• Pestronk A, Adams RN, Clawson L, Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis. Neurology 1988;38(9):1457–61.
   PubMedGoogle Scholar
• Nwosu VK, Royer JA, Stickler DE. Voltage gated potassium channel antibodies in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11(4):392–4.
   PubMed Web of Science ®Google Scholar
• Kimura F, Smith RG, Delbono O, Amyotrophic lateral sclerosis patient antibodies label Ca2+ channel alpha 1 subunit. Ann Neurol 1994;35(2):164–71.
   PubMedGoogle Scholar
• García Martín G, Perez Errazquin F, Chamorro Muñoz M, Romero Acebal M. Amyotrophic lateral sclerosis and anti-CV2 antibodies. Paraneoplastic association?. Neurologia 2007;22(6):406–9.
   PubMedGoogle Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(5):293–9.
   PubMed Web of Science ®Google Scholar
• Gallagher S, Winston SE, Fuller SA, Hurrell JG. Immunoblotting and immunodetection. Curr Protoc Cell Biol 2011;chap. 6:Unit 6.2.
   PubMedGoogle Scholar
• Pagani MR, Gonzalez LE, Uchitel OD. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol Res Int 2011;2011:1–11.
   Google Scholar
• Appel SH, Smith RG, Alexianu M, Increased intracellular calcium triggered by immune mechanisms in amyotrophic lateral sclerosis. Clin Neurosci 1995;3(6): 368–74.
   PubMedGoogle Scholar
• Appel SH, Engelhardt JI, Garcia J, Stefani E. Autoimmunity and ALS: a comparison of animal models of immune-mediated motor neuron destruction and human ALS. Adv Neurol 1991;56:405–12.
   PubMedGoogle Scholar
• Haggstrom B, Andersen PM, Hjalmarsson K, Autoimmunity and ALS: studies on antibodies to acetylcholinesterase in sera. Acta Neurol Scand 1997;95(2):111–14.
   PubMedGoogle Scholar
• Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 1990;47(11):1210–6.
   PubMed Web of Science ®Google Scholar
• Texidó L, Hernández S, Martín-Satué M, Sera from amyotrophic lateral sclerosis patients induce the non-canonical activation of NMDA receptors “in vitro”. Neurochem Int 2011;59(6):954–64.
   PubMedGoogle Scholar
• Freddo L, Yu RK, Latov N, Gangliosides GM1 and GD1b are antigens for IgM M-proteins in a patient with motor neuron disease. Neurology 1986;36(4):454–8.
   PubMedGoogle Scholar
• Pestronk A, Cornblath DR, Ilyas AA, A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24(1):73–8.
   PubMed Web of Science ®Google Scholar
• Latov N, Hays AP, Donofrio PD, Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease. Neurology 1988;38(5):763–8.
   PubMed Web of Science ®Google Scholar
• Nardelli E, Steck AJ, Barkas T, Motor neuron syndrome and monoclonal IgM with antibody activity against gangliosides GM1 and GD1b. Ann Neurol 1988;23(5):524–8.
   PubMedGoogle Scholar
• Schluep M, Steck AJ. Immunostaining of motor nerve terminals by IgM M protein with activity against gangliosides GM1 and GD1b from a patient with motor neuron disease. Neurology 1988;38(12):1890–2.
   PubMedGoogle Scholar
• Shy ME, Evans VA, Lublin FD, Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol 1989;25(5):511–3.
   PubMedGoogle Scholar
• Sadiq SA, Thomas FP, Kilidireas K, The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology 1990;40(7):1067–72.
   PubMed Web of Science ®Google Scholar
• Sanders KA, Rowland LP, Murphy PL, Motor neuron diseases and amyotrophic lateral sclerosis. GM 1 antibodies and paraproteinemia. Neurology 1993;43(2):418–20.
   PubMed Web of Science ®Google Scholar
• Pestronk A, Chaudhry V, Feldman EL, Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Ann Neurol 1990;27(3):316–26.
   PubMedGoogle Scholar
• Kornberg AJ, Pestronk A, Bieser K, The clinical correlates of high titer IgG anti-GM1 antibodies. Ann Neurol 1994;35(2):234–237.
   PubMedGoogle Scholar
• Marcus DM, Latov N, Hsi BP, Gillard BK. Measurement and significance of antibodies against GM1 ganglioside. Report of a workshop, 18 April 1989, Chicago, IL, USA. J Neuroimmunol 1989;25(2–3):255–9.
   PubMedGoogle Scholar
• Carpo M, Nobile-Orazio E, Meucci N, Anti-GD1a ganglioside antibodies in peripheral motor syndromes. Ann Neurol 1996;39(4):539–43.
   PubMedGoogle Scholar
• O'Hanlon GM, Veitch J, Gallardo E, Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity 2000;32(2):133–44.
   PubMedGoogle Scholar
• Mizutani K, Oka N, Kusunoki S, Amyotrophic lateral sclerosis with IgM antibody against gangliosides GM2 and GD2. Intern Med 2003;42(3):277–80.
   PubMedGoogle Scholar
• Stich O, Kleer B, Rauer S. Absence of paraneoplastic antineuronal antibodies in sera of 145 patients with motor neuron disease. J Neurol Neurosurg Psychiatry 2007;78(8): 883–5.
   PubMedGoogle Scholar
• Khwaja S, Sripathi N, Ahmad BK, Lennon VA. Paraneoplastic motor neuron disease with type 1 Purkinje cell antibodies. Muscle Nerve 1998;21(7):943–5.
   PubMedGoogle Scholar
• Distad BJ, Weiss MD. Paraneoplastic motor neuron disease associated with Purkinje cell autoantibody type 1. J Clin Neuromuscul Dis 2010;12(1):36–41.
   PubMedGoogle Scholar
• Verma A, Berger JR, Snodgrass S, Petito C. Motor neuron disease: a paraneoplastic process associated with anti-hu antibody and small-cell lung carcinoma. Ann Neurol 1996;40(1): 112–6.
   PubMedGoogle Scholar
• Forsyth PA, Dalmau J, Graus F, Motor neuron syndromes in cancer patients. Ann Neurol 1997;41(6): 722–30.
   PubMed Web of Science ®Google Scholar
• Ogawa M, Nishie M, Kurahashi K, Anti-Hu associated paraneoplastic sensory neuronopathy with upper motor neurone involvement. J Neurol Neurosurg Psychiatry 2004;75(7):1051–3.
   PubMedGoogle Scholar
• Brown RH, Jr, Johnson D, Ogonowski M, Weiner HL. Antineural antibodies in the serum of patients with amyotrophic lateral sclerosis. Neurology 1987;37(1):152–5.
   PubMedGoogle Scholar
• Kiernan JA, Hudson AJ. Anti-neurone antibodies are not characteristic of amyotrophic lateral sclerosis. Neuroreport 1993;4(4):427–30.
   PubMedGoogle Scholar
• Vigliani MC, Polo P, Chiò A, Patients with amyotrophic lateral sclerosis and cancer do not differ clinically from patients with sporadic amyotrophic lateral sclerosis. J Neurol 2000;247(10):778–82.
   PubMedGoogle Scholar
• Vianello M, Vitaliani R, Pezzani R, The spectrum of antineuronal autoantibodies in a series of neurological patients. J Neurol Sci 2004;220(1–2):29–36.
   PubMedGoogle Scholar
• Greiner A, Schmausser B, Petzold K, Neuronal targets of serum and cerebrospinal fluid autoantibodies in amyotrophic lateral sclerosis. Acta Neuropathol 1996;91(1):67–71.
   PubMedGoogle Scholar
• Irani SR, Alexander S, Waters P, Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133(9):2734–48.
   PubMed Web of Science ®Google Scholar
• Rueff L, Graber JJ, Bernbaum M, Kuzniecky RI. Voltage-gated potassium channel antibody-mediated syndromes: a spectrum of clinical manifestations. Rev Neurol Dis 2008;5(2):65–72.
   PubMedGoogle Scholar
• Lai M, Huijbers MG, Lancaster E, Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9(8):776–85.
   PubMed Web of Science ®Google Scholar
• Lancaster E, Huijbers MG, Bar V, Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011;69(2):303–11.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Lancaster E, Martinez-Hernandez E, Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10(1):63–74.
   PubMed Web of Science ®Google Scholar
• Kürtüncü M, Kaya D, Zuliani L, CACNA1H antibodies associated with headache with neurological deficits and cerebrospinal fluid lymphocytosis (HaNDL). Cephalalgia 2013;33(2):123–9.
   PubMedGoogle Scholar
• Vural B, Uğurel E, Tüzün E, Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease. J Neuroimmunol 2011;239(1–2):91–7.
   PubMedGoogle Scholar